LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ortho Presents Broad Menu of High-Performing Assays at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 11 Apr 2022
Image: Ortho’s assays are optimized to meet changing testing needs (Photo courtesy of Ortho Clinical Diagnostics)
Image: Ortho’s assays are optimized to meet changing testing needs (Photo courtesy of Ortho Clinical Diagnostics)

Ortho Clinical Diagnostics (Raritan, NJ, USA) presented its comprehensive, fully integrated and completely scalable solutions, including its broad menu of high-performing assays, at EUROMEDLAB 2022.

Ortho presented its VITROS Dashboards, a web-based system designed to provide productivity information regarding analyzers, test volumes, workload balance, HIT (Hemolysis, Icterus, Turbidity) levels, and reagent efficiency. The highlight of Ortho’s presentation at EUROMEDLAB 2022 was its VITROS COVID-19 Performance Dashboard - a web-based system designed to provide productivity information regarding Ortho analyzers, including volumes, workload balance, HIT levels, and reagent efficiency for each site within the health system. The VITROS COVID-19 Performance Dashboard is located within the Ortho Plus environment and is an extension of Ortho’s e-Connectivity Technology. e-Connectivity not only supports the delivery of timely and accurate results to patients and physicians, it also protects patient data.

With the ability to monitor antibody testing trends, users can adjust staffing and workflow according to their testing volumes. Labs can quantify the number of samples processed the first time - even when HIT interference is present, giving them the ability to spot negative trends in order to take action. With the VITROS COVID-19 Performance Dashboard, users have access to data that will give them a better understanding of the virus, including its impact on their lab and hospital, to adjust accordingly. With signal to cut off values, labs can see the separation between positive and negative results, giving them confidence in their results. The VITROS COVID-19 Performance Dashboard assisting users in their quest to improve laboratory efficiency and decision support while providing the best care for their patients and staff.

IN Addition, Ortho demonstrated how laboratories can contribute to patient blood management initiatives by minimizing impact of common interferences amongst other challenges. The company also exhibited its broad menu of high-performing assays that are optimized to meet the changing testing needs of laboratories.

Related Links:
Ortho Clinical Diagnostics 

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more